The mechanisms underlying the phenotypes appear to be associated with the inhibitory influence of AGER1 on ferroptosis, which is dependent on the regulation of Sirt4, and suggest that AGER1 is a useful therapeutic target to prevent fibrosis progression in patients with NASH with T2DM. The gene discussed is DDOST; the disease is metabolic dysfunction-associated steatohepatitis.